Patient eligibility
Cancer, breast cancer
CANCER, BREAST CANCER
Eligible patients had newly diagnosed, potentially resectable, pathologically confirmed invasive stage 2 and 3 breast cancer (clinical T2, T3, T4a-c, N0-2, and M0), ER- and/or progesterone receptor (PR)-positive, Her2/neu-negative [The protocol was amended once to allow premenopausal women whose ovarian function was to be suppressed with goserelin to participate in the study. The protocol was reviewed and approved by the participating institution, and the study followed the Declaration of Helsinki and Good Clinical Practice guidelines. All patients gave informed consent. This study is registered on the clinical trial website of the US National Cancer Institute (